Premium
Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease
Author(s) -
Edfors Kajsa,
Ståhlberg Dagny,
Söderman Charlotte
Publication year - 2016
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12336
Subject(s) - medicine , apheresis , inflammatory bowel disease , single center , gastroenterology , retrospective cohort study , granulocyte , ulcerative colitis , refractory (planetary science) , adverse effect , monocyte , leukapheresis , surgery , disease , platelet , cd34 , physics , stem cell , astrobiology , biology , genetics
Patients with active inflammatory bowel disease (IBD) have elevated and activated myeloid leukocytes, which infiltrate the intestinal mucosa. A significant proportion of IBD patients do not respond adequately to conventional treatment regimes. Studies have suggested that treatment with granulocyte monocyte apheresis (GMA) could be a safe and efficacious alternative for these patients. We evaluated the efficacy and safety of granulocyte/monocyte apheresis in patients with IBD in a retrospective cohort study, conducted from a single center in Stockholm. Clinical details from consecutive apheresis treated patients were retrospectively reviewed from 2004 to 2012. A total of 37 patients were included, 23 patients with ulcerative colitis (UC) and 14 with Crohn's disease (CD). Clinical response was seen in 11 patients (30%) and complete remission in 11 patients (30%). The remission rate was higher in UC patients compared to CD patients, 39% ( N = 9) and 14% ( N = 2) respectively. A total of 9 patients experienced adverse events. Most frequently reported was headache ( N = 4). GMA seems to be a valuable adjuvant treatment regime in the care of patients with refractory IBD.